<DOC>
	<DOCNO>NCT01119794</DOCNO>
	<brief_summary>The purpose study : Investigate Overall Response Rate ( ORR ) combination ofatumumab bortezomib patient low-grade B-cell non-Hodgkin lymphoma ( LG-NHL ) relapse beyond 6 month previous rituximab-containing regimen .</brief_summary>
	<brief_title>Ofatumumab Bortezomib Patients With Low-grade B-cell Non-hodgkin Lymphoma That Relapse After Rituximab</brief_title>
	<detailed_description>41 patient enrolled trial low grade lymphoma give Ofatumumab 1000 mg Bortezomib IV 1.6 mg/m2 weekly time 4 treatment receive maintenance treatment 2 agent every 2 month 1 year unless disease progression .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patients require histologically confirm lymphoma accord WHO/Revised EuropeanAmerican Lymphoma classification , include Bcell small lymphocytic lymphoma ( SLL ) ; marginal zone lymphoma ( MZL ) ; follicular lymphoma ( FL ) , grade 1 , 2 , 3 ; mantle cell lymphoma ( MCL ) ; Waldenström macroglobulinemia . Prior history transform lymphoma permit long recent biopsy reveal evidence aggressive lymphoma &gt; 3years since prior aggressive lymphoma Patients must measurable disease ( defined 1 cm spiral compute tomography scan ) Relapse disease beyond 6 month rituximabcontaining regimen Patients receive three prior line conventional cytotoxic therapy , require stop receive cytotoxic chemotherapy least 4 week study enrollment Absolute neutrophil count &gt; 1,500/uL Platelet &gt; 100,000/uL ( know lymphomatous involvement bone marrow , absolute neutrophil count &gt; 750/uL platelet count &gt; 50,000/uL ) within 14 day enrollment . Total bilirubin &lt; 1.5 x upper institutional limit normal ( ULN ) , AST ALT &lt; 2.5 x ULN ( &lt; 3 x ULN patient liver involvement ) ; alkaline phosphatase &lt; 2.5x upper limit normal ; creatinine &lt; 2mg/dl within 14 day enrollment . ECOG performance status 0 2 Minimum life expectancy 6 month Age old 18 year Voluntary , sign write informed consent performance studyrelated procedure part normal medical care , understand consent may withdraw subject time without prejudice future medical care . Female subject either postmenopausal surgically sterilize willing use acceptable method birth control ( i.e. , hormonal contraceptive , intrauterine device , diaphragm spermicide , condom spermicide , abstinence ) duration study . Male subject agrees use acceptable method contraception duration study . Subjects current active hepatic biliary disease asymptomatic gallstone , liver metastasis stable chronic liver disease per investigator assessment ) Documented infection HIV Positive serology Hepatitis B define positive test HBsAg . In addition , negative HBsAg HBcAb positive ( regardless HBsAb status ) , HB DNA test perform positive subject exclude . Central nervous system meningeal involvement lymphoma Prior transplantation Contraindication drug contain chemotherapy regimens Any serious active disease comorbid condition would impair protocol treatment . Diagnosed treat another malignancy within 3 year enrollment , exception complete resection basal call carcinoma squamous cell carcinoma skin , situ malignancy , lowrisk prostate cancer curative therapy . Prior treatment antiCD20 monoclonal antibody , exception rituximab , proteasome inhibitor . Patient Grade 2 peripheral neuropathy within 14 day enrollment . Myocardial infarction within 6 month prior enrollment New York Heart Association ( NYHA ) Class III IV heart failure ( see section 8.4 ) , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality . Prior study entry , ECG abnormality screen document investigator medically relevant . Patient hypersensitivity boron mannitol . Female subject pregnant breastfeeding . Confirmation subject pregnant must establish negative serum pregnancy test result obtain screening . A pregnancy test must perform within 7 day prior study drug . Pregnancy test require postmenopausal surgically sterilize woman . Patient receive investigational drug within 4 week enrollment 5 half life investigational agent . Serious medical psychiatric illness likely interfere participation clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>B-cell small lymphocytic lymphoma</keyword>
	<keyword>marginal zone lymphoma</keyword>
	<keyword>follicular lymphoma</keyword>
	<keyword>mantle cell lymphoma</keyword>
	<keyword>Waldenström macroglobulinemia .</keyword>
	<keyword>Low Grade B cell Non-Hodgkins Lymphoma</keyword>
</DOC>